From one therapy to a scalable delivery infrastructure.
Transdermal patches are used widely, but current technology suffers from adhesion failures, skin irritation and inconsistent drug delivery. Innovation has failed to keep pace with modern materials and manufacturing. LORAI is closing that gap.
This is not a product problem. It is a systems problem.
Continuous therapy over decades needs more than a better adhesive. It needs product performance, a regulatory pathway, reliable supply and real-world data working together.
- 01
Product performance
- Designed for adhesion and skin tolerability
- Consistent multi-day wear
- Safe formulation for decades-long use
- 02
Regulatory advantage
- Bioequivalence pathway by design
- Built to modern adhesion standards
- Global regulatory roadmap from day one
- 03
Supply reliability
- Global manufacturing partnerships
- Scalable patch production
- Reliable, uninterrupted supply
- 04
Digital & data
- Telehealth and digital pharmacy channels
- Predictable demand through recurring use
- Real-world data on adherence, wear and outcomes
A high-performance, user-centric estradiol patch
Built on advanced medical materials available today, with a bioequivalence pathway by design.
Design intent
Designed for adhesion and skin tolerability; consistent multi-day wear; a formulation safe for decades-long use.
Targets
50% lower dermal irritation versus generics, a 50% smaller patch footprint, and intact adhesion through days 4–7.
Regulatory
Efficient bioequivalence pathway; built to meet modern adhesion standards; global regulatory roadmap from day one.
Supply
Global manufacturing partnerships and scalable patch production for reliable, uninterrupted supply.
A delivery platform, not a single product.
Compound-agnostic architecture with controlled release, longer wear, skin-compatible non-irritant materials and higher bioavailability.
Prescription therapeutics
- Hormonal continuity for men and women
- Neurology
- Palliative care
- Oncology supportive care
Consumer & OTC
- Vitamins and micronutrients
- Sleep
- Energy and cognition
- Pain and athletic recovery
Enabling multiple drug categories
Molecules delivered intravenously today, where a controlled multi-day transdermal option would change care.
| Molecule | Indication | Current delivery |
|---|---|---|
| Estrogen | Menopause hormone therapy (MHT) | Oral, transdermal |
| Ketamine / esketamine | Mental health, postpartum depression | IV |
| Dexmedetomidine | Short-term sedation, ICU and palliative care | IV; transdermal in development |
| Haloperidol | Antipsychotic, delirium, mental conditions, palliative care | IV |
| Apomorphine | Parkinson’s disease | IV |
Transdermal estradiol in prostate cancer
Clinical validation of better overall tolerability and quality of life versus standard therapies, published in the New England Journal of Medicine in March 2026.
Langley RE et al. (2026). Transdermal estradiol patches in locally advanced prostate cancer. New England Journal of Medicine.
Have a molecule that needs better delivery?
We evaluate partner molecules against the Gen-2 platform, from feasibility through pilot bioequivalence.